Gemtuzumab ozogamicin has recently acquired approval for r/r CD33+ AML in pediatric patients and tisagenlecleucel for r/r B-ALL in relapse post-transplant or in second or later relapse. The gene discussed is CD33; the disease is acute myeloid leukemia.